Amerisource Health Services Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Amerisource Health Services Pharmaceutical Import Records from India — 8 Products, $8.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amerisource Health Services — Pharmaceutical Importer Profile (2026) | 8 Products, $8.9M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Amerisource Health Services?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$12.8M	374	28.6%
Zydus Lifesciences Limited	$7.1M	336	15.8%
Lupin Limited	$5.8M	188	13.1%
Unichem Laboratories Limited	$3.1M	160	6.9%
Aurobindo Pharma Limited	$2.8M	97	6.2%
Intas Pharmaceuticals Limited	$2.6M	95	5.8%
Macleods Pharmaceuticals Limited	$2.0M	78	4.5%
Cadila Healthcare Limited	$1.9M	65	4.3%
Dr.reddy's Laboratories Limited	$1.8M	60	4.0%
Alkem Laboratories Limited	$1.1M	57	2.6%
Cipla Limited	$996.5K	72	2.2%
Ajanta Pharma Limited	$804.3K	33	1.8%
Micro Labs Limited	$704.6K	38	1.6%
Gopaldas Visram And Company Limited	$341.0K	40	0.8%
Dr Reddys Laboratories Limited	$340.1K	13	0.8%
Gopaldas Visram Company Limited	$321.3K	28	0.7%
Somerset Therapeutics Limited	$86.1K	12	0.2%
Gland Pharma Limited	$80.5K	3	0.2%
Wintac Limited	$4.8K	2	0.0%

Amerisource Health Services sources from 19 verified Indian suppliers across 967 distinct formulations. The supply base is diversified across 19 suppliers, reducing single-source dependency risk.

What Formulations Does Amerisource Health Services Import?

Formulation	Value	Ships
Pharmaceutical medicine for human	$1.0M	30
Pharmaceuticals- gabapentin TAB 600MG	$900.0K	18
Pharmaceuticals- gabapentin TAB 600MG 500 (BP)	$767.6K	16
Pharmaceuticals- gabapentin TAB 800MG	$550.0K	11
Palonosetron hydrochloride injection	$450.0K	9
Metoprolol succinate extended release	$432.5K	10
Pharmaceuticals zonisamide cap 100MG 100	$419.5K	9

What Products Does Amerisource Health Services Import?

Top Products by Import Value

1Carvedilol$4.0M 2Montelukast$2.2M 3Fluconazole$750.0K 4Glimepiride$704.6K 5Etoposide$350.0K 6Anastrozole$338.7K

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Carvedilol	Cardiovascular	$4.0M	129	4.1%	7
2	Montelukast	Respiratory	$2.2M	44	1.3%

Key Metrics

Total Import Value$8.9M

Products8

Shipments282

Categories6

CountryUnited States

#1 Rankings1

Indian Suppliers19

Formulations967

Top Categories

Cardiovascular44.9%

Respiratory24.8%

Last updated: March 28, 2026

Amerisource Health Services — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amerisource Health Services LLC is a U.S.-based healthcare distributor specializing in the importation and distribution of pharmaceutical products. The company operates primarily from its facility located at 2550 John Glenn Ave, Columbus, Ohio 43217. Established in 1986, Amerisource Health Services has been a key player in the pharmaceutical supply chain for over four decades.

The company focuses on importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This strategic approach allows Amerisource Health Services to cater to the diverse needs of healthcare providers by ensuring a steady supply of ready-to-use medications. Their clientele includes hospitals, clinics, pharmacies, and other healthcare facilities across the United States.

2Distribution Network

Amerisource Health Services operates a centralized distribution center at its Columbus, Ohio location. This facility serves as the primary hub for receiving, storing, and dispatching pharmaceutical products. The strategic positioning of this center enables efficient logistics and timely delivery to various healthcare providers throughout the United States. While specific details about additional warehouse locations or international logistics capabilities are not publicly disclosed, the company's extensive import records indicate a robust and well-established distribution network.

Supplier Relationship Intelligence — Amerisource Health Services

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amerisource Health Services demonstrates a significant concentration in its sourcing strategy, with a total import value of $8.9 million USD from India across 282 shipments. The company's portfolio is heavily concentrated, with the top five products accounting for 90% of the total import value. This concentration indicates a strategic focus on high-demand medications, which can lead to cost efficiencies and streamlined operations. However, such dependency also poses risks, including potential supply chain disruptions if any of these key suppliers face operational challenges. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import activity over the years. Nonetheless, diversifying the supplier base could mitigate risks associated with over-reliance on a limited number of suppliers.

2Supply Chain Resilience

Amerisource Health Services' supply chain resilience is supported by its diversified sourcing from 19 unique Indian suppliers, encompassing 967 unique formulations. This diversity in suppliers and product offerings enhances the company's ability to adapt to market changes and potential disruptions. While the primary shipping routes and regulatory compliance statuses of these suppliers are not detailed, the consistent import records suggest adherence to international shipping standards and regulatory requirements. To further bolster resilience, establishing relationships with additional backup suppliers and continuously monitoring the regulatory compliance of key partners would be prudent.

3Strategic Implications

The sourcing pattern of Amerisource Health Services, characterized by a concentrated focus on high-demand pharmaceutical products from a diverse set of Indian suppliers, positions the company competitively in the U.S. market. This strategy enables the company to offer a reliable supply of essential medications, catering to the needs of various healthcare providers. For Indian exporters, this presents an opportunity to engage with a stable and established importer, provided they can meet the quality standards and regulatory requirements expected by U.S. authorities. Expanding the range of products offered and ensuring consistent quality can enhance the attractiveness of Indian exporters to companies like Amerisource Health Services.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth the standards for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring that imported pharmaceuticals meet the required standards. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name counterpart.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent. Importers must register with the FDA and comply with the Drug Establishment Registration and Drug Listing requirements. Good Manufacturing Practice (GMP) certification is crucial; the FDA recognizes certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized bodies to facilitate smooth importation processes. Additionally, wholesale distribution authorization is required, which involves meeting specific state and federal regulations governing the distribution of pharmaceutical products.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to confirm their safety, efficacy, and quality. Stability studies are essential to determine the shelf-life and storage conditions of the products. Labeling requirements include providing information in English, detailing the drug's name, dosage form, strength, route of administration, and storage conditions. Serialization mandates, such as the Drug Supply Chain Security Act (DSCSA), require unique identifiers on drug packages to enhance traceability and prevent counterfeit products from entering the supply chain.

4Recent Regulatory Changes

Between 2024 and 2026, several policy changes have impacted the importation of Indian pharmaceuticals into the United States. The FDA has implemented stricter guidelines for bioequivalence studies, necessitating more comprehensive data for ANDA approvals. There has been an increased emphasis on supply chain security, with enhanced requirements for serialization and track-and-trace systems to combat counterfeit drugs. Additionally, the FDA has introduced expedited pathways for approving generics to address drug shortages, which may benefit Indian exporters.

TransData Nexus Research · United States regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Amerisource Health Services identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Amerisource Health Services's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 282 individual customs records matching Amerisource Health Services.
5.Supplier Verification: Amerisource Health Services sources from 19 verified Indian suppliers across 967 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

8 Products Tracked

6 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Amerisource Health Services

Amerisource Health Services — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Amerisource Health Services?

What Formulations Does Amerisource Health Services Import?

What Products Does Amerisource Health Services Import?

Top Products by Import Value

Import Portfolio — Top 8 by Import Value

Key Metrics

Top Categories

Amerisource Health Services — Corporate Profile & Information

1Company Overview

2Distribution Network

Amerisource Health Services Therapeutic Categories — 6 Specializations

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Amerisource Health Services

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Amerisource Health Services — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Amerisource Health Services

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Amerisource Health Services

What products does Amerisource Health Services import from India?

Who supplies pharmaceuticals to Amerisource Health Services from India?

What is Amerisource Health Services's total pharmaceutical import value?

What therapeutic categories does Amerisource Health Services focus on?

Get Full Amerisource Health Services Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology